KI-7 is an A2B adenosine receptor-positive allosteric modulator (PAM). KI-7 enhances cAMP accumulation induced by the non-selective A2B adenosine receptor agonist (activator) NECA (EC50=445.8 nM). KI-7 also enhanced cAMP accumulation induced by the selective A2B adenosine receptor agonist (activator)s BAY 60-6583 and adenosine, with EC50s of 2390 nM and 2550 nM, respectively.

Physicochemical Properties

Molecular Formula	C23H18N2O2
Molecular Weight	354.401225566864
Exact Mass	354.136
CAS #	1489263-00-4
PubChem CID	73350966
Appearance	White to off-white solid powder
LogP	4.3
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	5
Heavy Atom Count	27
Complexity	523
Defined Atom Stereocenter Count	0
SMILES	O=C(C(NC1C=CC=CC=1)=O)C1=CN(CC2C=CC=CC=2)C2C=CC=CC=21
InChi Key	MQMGZFRIEZRHHJ-UHFFFAOYSA-N
InChi Code	InChI=1S/C23H18N2O2/c26-22(23(27)24-18-11-5-2-6-12-18)20-16-25(15-17-9-3-1-4-10-17)21-14-8-7-13-19(20)21/h1-14,16H,15H2,(H,24,27)
Chemical Name	2-(1-benzylindol-3-yl)-2-oxo-N-phenylacetamide
Synonyms	KI7 KI 7 KI-7
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro

Runx2 and Osterix mRNA expression can be significantly increased by KI-7 (1 μM; 5–21 days; mesenchymal stem cells) [1]. Cell viability is significantly increased at both differentiation stages by KI-7 (1 μM; 15–21 days) [1]. It has been demonstrated that KI-7, a positive allosteric modulator of the A2B adenosine receptor in MSCs, enhances the in vitro osteoblast differentiation-promoting actions of both adenosine and synthetic orthosteric A2B adenosine receptor agonists. KI-7, BAY 60-6583, and NECA all significantly increased the production of IL-6. Even though this effect only becomes noticeable at day 21, KI-7 amplifies the effects of orthotopic agonists at both differentiation stages [1].

References

[1]. Allosteric modulators of human A2B adenosine receptor. Biochim Biophys Acta. 2014;1840(3):1194-1203. [2]. Osteoblast differentiation and survival: A role for A2B adenosine receptor allosteric modulators. Biochim Biophys Acta. 2014;1843(12):2957-2966.

Solubility Data

Solubility (In Vitro)

DMSO : ~250 mg/mL (~705.42 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.8217 mL	14.1084 mL	28.2167 mL
	5 mM	0.5643 mL	2.8217 mL	5.6433 mL
	10 mM	0.2822 mL	1.4108 mL	2.8217 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.